NEW YORK (GenomeWeb News) – Theradiag today announced that Oséo has provided it €1.2 million ($1.6 million) to develop new diagnostic kits as part the French firm's participation in a project to develop RNA-targeting therapeutics and diagnostics aimed at HIV/AIDS and obesity.

NEW YORK (GenomeWeb News) – The French government has provided €13.4 million ($17.4 million) to fund the Innovative MODels Initiative (IMODI), a partnership aimed at facilitating the development of new cancer treatments.

NEW YORK (GenomeWeb News) – Exonhit today said it has been awarded €1.9 million ($2.4 million) to participate in a project aimed at developing new treatments for cancers and tools to identify patients who may be best candidates for the treatments.

The funding will be used primarily to set up a European multi-center clinical trial for the validation of a molecular test to predict non-response to anti-TNF treatment, in particular Remicade.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

Funded by the French innovation agency OSEO, the collaboration calls for the companies to develop a prototype blood-based protein biomarker test for Alzheimer's disease as well as a therapeutic for the disease and a companion diagnostic.

BioIntelligence, coordinated by French industrial firm Dassault Systèmes, will bring together pharma firms, software companies, and academic and government research labs to adapt product lifecycle management, or PLM, tools for use in the life sciences.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.